A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Recruiting now · Phase 2
Conditions studied: Metastatic Castration-Resistant Prostate Cancer
In brief
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Key facts
- Study ID
- NCT06842498
- Run by
- Kyntra Bio
- People needed
- 75
- Starts
- 2026-02-22
- Expected to finish
- 2028-03-31
- Last updated by the study team
- 2026-05-22
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Western Regional Medical Center - City of Hope Phoenix Goodyear — Goodyear, Arizona, United States (enrolling)
- HonorHealth Research Institute — Scottsdale, Arizona, United States (enrolling)
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona, United States (enrolling)
- VA Greater Los Angeles Healthcare System — Los Angeles, California, United States (enrolling)
- UCLA Clark Urology Center — Los Angeles, California, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- New Haven Hospital - Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
- Bioresearch Partner - Aventura — Aventura, Florida, United States (enrolling)
- Bioresearch Partner - Hialeah — Hialeah, Florida, United States (enrolling)
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
- East Jefferson General Hospital Metairie — New Orleans, Louisiana, United States (enrolling)
- New Mexico Oncology Hematology Consultants, Ltd. — Albuquerque, New Mexico, United States (enrolling)
- Duke University Medical Center - Duke Cancer Center — Durham, North Carolina, United States (enrolling)
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
- Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States (enrolling)
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (enrolling)
- Oncology Consultants — Houston, Texas, United States (enrolling)
- University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- University of Washington Medical Center — Seattle, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.